127 related articles for article (PubMed ID: 8683250)
1. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia.
Juliusson G; Christiansen I; Hansen MM; Johnson S; Kimby E; Elmhorn-Rosenborg A; Liliemark J
J Clin Oncol; 1996 Jul; 14(7):2160-6. PubMed ID: 8683250
[TBL] [Abstract][Full Text] [Related]
2. Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Karlsson K; Strömberg M; Liliemark J; Delannoy A; Johnson SA; Porwit A; Kimby E; Lärfars G; Cristiansen I; Nilsson G; Celsing F; Sundström G; Luthman M; Tidefelt U; Wallvik J; Juliusson G
Br J Haematol; 2002 Mar; 116(3):538-48. PubMed ID: 11849209
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
4. High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.
Juliusson G; Liliemark J
J Clin Oncol; 1993 Apr; 11(4):679-89. PubMed ID: 8097528
[TBL] [Abstract][Full Text] [Related]
5. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dwilewicz-Trojaczek J; Stella-Hołowiecka B; Wołowiec D
Hematol J; 2002; 3(5):244-50. PubMed ID: 12391542
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
Juliusson G; Liliemark J
Ann Oncol; 1996 Apr; 7(4):373-9. PubMed ID: 8805929
[TBL] [Abstract][Full Text] [Related]
7. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
[TBL] [Abstract][Full Text] [Related]
8. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
Tallman MS; Hakimian D; Zanzig C; Hogan DK; Rademaker A; Rose E; Variakojis D
J Clin Oncol; 1995 Apr; 13(4):983-8. PubMed ID: 7707127
[TBL] [Abstract][Full Text] [Related]
9. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP; Karlsson K; Strömberg M; Jønsson V; Gill D; Hammerström J; Hertzberg M; McLennan R; Uggla B; Norman J; Wallvik J; Sundström G; Johansson H; Brandberg Y; Liliemark J; Juliusson G;
Leuk Lymphoma; 2014 Dec; 55(12):2769-77. PubMed ID: 24524339
[TBL] [Abstract][Full Text] [Related]
10. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
12. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
[TBL] [Abstract][Full Text] [Related]
13. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).
Delannoy A; Martiat P; Gala JL; Deneys V; Ferrant A; Bosly A; Schieff JM; Michaux JL
Leukemia; 1995 Jul; 9(7):1130-5. PubMed ID: 7630184
[TBL] [Abstract][Full Text] [Related]
14. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D;
Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059
[TBL] [Abstract][Full Text] [Related]
15. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).
Betticher DC; Ratschiller D; Hsu Schmitz SF; von Rohr A; Hess U; Zulian G; Wernli M; Tichelli A; Tobler A; Fey MF; Cerny T
Ann Oncol; 1998 Jul; 9(7):721-6. PubMed ID: 9739437
[TBL] [Abstract][Full Text] [Related]
16. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y
Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268
[TBL] [Abstract][Full Text] [Related]
18. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
Robak T; Błasinka-Morawiec M; Krykowski E; Kasznicki M; Płuzanska A; Potemski P; Hellmann A; Zaucha JM; Lewandowski K; Dmoszynska A; Hansz J; Komarnicki M; Konopka L; Durzynski T; Ceglarek B; Sikorska A; Kotlarek-Haus S; Mazur G; Urasinski I; Zdziarska B; Maj S; Kopec I; Skotnicki AB; Dwilewicz-Trojaczek J; Grieb P
Leuk Lymphoma; 1996 Aug; 22(5-6):509-14. PubMed ID: 8882965
[TBL] [Abstract][Full Text] [Related]
19. Cladribine in the treatment of chronic lymphocytic leukemia.
Robak T
Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
[TBL] [Abstract][Full Text] [Related]
20. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
Robak T; Błoński JZ; Urbańska-Ryś H; Błasińska-Morawiec M; Skotnicki AB
Leukemia; 1999 Apr; 13(4):518-23. PubMed ID: 10214856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
